134 related articles for article (PubMed ID: 23878023)
1. Quantitative (31)P HR-MAS MR spectroscopy for detection of response to PI3K/mTOR inhibition in breast cancer xenografts.
Esmaeili M; Bathen TF; Engebråten O; Mælandsmo GM; Gribbestad IS; Moestue SA
Magn Reson Med; 2014 Jun; 71(6):1973-81. PubMed ID: 23878023
[TBL] [Abstract][Full Text] [Related]
2. Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer.
Moestue SA; Dam CG; Gorad SS; Kristian A; Bofin A; Mælandsmo GM; Engebråten O; Gribbestad IS; Bjørkøy G
Breast Cancer Res; 2013 Feb; 15(1):R16. PubMed ID: 23448424
[TBL] [Abstract][Full Text] [Related]
3. In vivo ³¹P magnetic resonance spectroscopic imaging (MRSI) for metabolic profiling of human breast cancer xenografts.
Esmaeili M; Moestue SA; Hamans BC; Veltien A; Kristian A; Engebråten O; Maelandsmo GM; Gribbestad IS; Bathen TF; Heerschap A
J Magn Reson Imaging; 2015 Mar; 41(3):601-9. PubMed ID: 24532410
[TBL] [Abstract][Full Text] [Related]
4. Melanoma tumors acquire a new phospholipid metabolism phenotype under cystemustine as revealed by high-resolution magic angle spinning proton nuclear magnetic resonance spectroscopy of intact tumor samples.
Morvan D; Demidem A; Papon J; De Latour M; Madelmont JC
Cancer Res; 2002 Mar; 62(6):1890-7. PubMed ID: 11912170
[TBL] [Abstract][Full Text] [Related]
5. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.
Fuereder T; Wanek T; Pflegerl P; Jaeger-Lansky A; Hoeflmayer D; Strommer S; Kuntner C; Wrba F; Werzowa J; Hejna M; Müller M; Langer O; Wacheck V
Clin Cancer Res; 2011 Aug; 17(16):5322-32. PubMed ID: 21712451
[TBL] [Abstract][Full Text] [Related]
6. Response of choline metabolites to docetaxel therapy is quantified in vivo by localized (31)P MRS of human breast cancer xenografts and in vitro by high-resolution (31)P NMR spectroscopy of cell extracts.
Morse DL; Raghunand N; Sadarangani P; Murthi S; Job C; Day S; Howison C; Gillies RJ
Magn Reson Med; 2007 Aug; 58(2):270-80. PubMed ID: 17654590
[TBL] [Abstract][Full Text] [Related]
7. Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models.
Moestue SA; Borgan E; Huuse EM; Lindholm EM; Sitter B; Børresen-Dale AL; Engebraaten O; Maelandsmo GM; Gribbestad IS
BMC Cancer; 2010 Aug; 10():433. PubMed ID: 20716336
[TBL] [Abstract][Full Text] [Related]
8. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models.
Al-Saffar NM; Troy H; Ramírez de Molina A; Jackson LE; Madhu B; Griffiths JR; Leach MO; Workman P; Lacal JC; Judson IR; Chung YL
Cancer Res; 2006 Jan; 66(1):427-34. PubMed ID: 16397258
[TBL] [Abstract][Full Text] [Related]
9. Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy.
Sitter B; Bathen TF; Singstad TE; Fjøsne HE; Lundgren S; Halgunset J; Gribbestad IS
NMR Biomed; 2010 May; 23(4):424-31. PubMed ID: 20101607
[TBL] [Abstract][Full Text] [Related]
10. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
Serra V; Markman B; Scaltriti M; Eichhorn PJ; Valero V; Guzman M; Botero ML; Llonch E; Atzori F; Di Cosimo S; Maira M; Garcia-Echeverria C; Parra JL; Arribas J; Baselga J
Cancer Res; 2008 Oct; 68(19):8022-30. PubMed ID: 18829560
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of 31P high-resolution magic angle spinning of intact tissue samples.
Payne GS; Troy H; Vaidya SJ; Griffiths JR; Leach MO; Chung YL
NMR Biomed; 2006 Aug; 19(5):593-8. PubMed ID: 16645958
[TBL] [Abstract][Full Text] [Related]
12. Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model.
Kim E; Tunset HM; Cebulla J; Vettukattil R; Helgesen H; Feuerherm AJ; Engebråten O; Mælandsmo GM; Johansen B; Moestue SA
BMC Cancer; 2016 Mar; 16():191. PubMed ID: 26951085
[TBL] [Abstract][Full Text] [Related]
13. 13C high-resolution-magic angle spinning MRS reveals differences in glucose metabolism between two breast cancer xenograft models with different gene expression patterns.
Grinde MT; Moestue SA; Borgan E; Risa Ø; Engebraaten O; Gribbestad IS
NMR Biomed; 2011 Dec; 24(10):1243-52. PubMed ID: 21462378
[TBL] [Abstract][Full Text] [Related]
14. Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters.
Sitter B; Lundgren S; Bathen TF; Halgunset J; Fjosne HE; Gribbestad IS
NMR Biomed; 2006 Feb; 19(1):30-40. PubMed ID: 16229059
[TBL] [Abstract][Full Text] [Related]
15. Investigation of metabolite changes in the transition from pre-invasive to invasive cervical cancer measured using (1)H and (31)P magic angle spinning MRS of intact tissue.
De Silva SS; Payne GS; Thomas V; Carter PG; Ind TE; deSouza NM
NMR Biomed; 2009 Feb; 22(2):191-8. PubMed ID: 18833545
[TBL] [Abstract][Full Text] [Related]
16. Predicting long-term survival and treatment response in breast cancer patients receiving neoadjuvant chemotherapy by MR metabolic profiling.
Cao MD; Sitter B; Bathen TF; Bofin A; Lønning PE; Lundgren S; Gribbestad IS
NMR Biomed; 2012 Feb; 25(2):369-78. PubMed ID: 21823183
[TBL] [Abstract][Full Text] [Related]
17. The dual PI3K/mTOR inhibitor NVP-BEZ235 prevents epithelial-mesenchymal transition induced by hypoxia and TGF-β1.
Lin G; Gai R; Chen Z; Wang Y; Liao S; Dong R; Zhu H; Gu Y; He Q; Yang B
Eur J Pharmacol; 2014 Apr; 729():45-53. PubMed ID: 24561043
[TBL] [Abstract][Full Text] [Related]
18. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor is an effective radiosensitizer for colorectal cancer.
Chen YH; Wei MF; Wang CW; Lee HW; Pan SL; Gao M; Kuo SH; Cheng AL; Teng CM
Cancer Lett; 2015 Feb; 357(2):582-90. PubMed ID: 25497009
[TBL] [Abstract][Full Text] [Related]
19. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma.
Doghman M; Lalli E
Mol Cell Endocrinol; 2012 Nov; 364(1-2):101-4. PubMed ID: 22960230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
